ID   E2AK2_HUMAN             Reviewed;         551 AA.
AC   P19525; A8K3P0; Q52M43; Q9UIR4;
DT   01-FEB-1991, integrated into UniProtKB/Swiss-Prot.
DT   01-MAY-1991, sequence version 2.
DT   05-OCT-2010, entry version 133.
DE   RecName: Full=Interferon-induced, double-stranded RNA-activated protein kinase;
DE            EC=2.7.11.1;
DE   AltName: Full=Eukaryotic translation initiation factor 2-alpha kinase 2;
DE            Short=eIF-2A protein kinase 2;
DE   AltName: Full=Interferon-inducible RNA-dependent protein kinase;
DE   AltName: Full=P1/eIF-2A protein kinase;
DE   AltName: Full=Protein kinase RNA-activated;
DE            Short=PKR;
DE   AltName: Full=p68 kinase;
GN   Name=EIF2AK2; Synonyms=PKR, PRKR;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA], AND PROTEIN SEQUENCE OF 101-118 AND
RP   309-325.
RX   MEDLINE=90322433; PubMed=1695551; DOI=10.1016/0092-8674(90)90374-N;
RA   Meurs E., Chong K., Galabru J., Thomas N.S.B., Kerr I.M.,
RA   Williams B.R.G., Hovanessian A.G.;
RT   "Molecular cloning and characterization of the human double-stranded
RT   RNA-activated protein kinase induced by interferon.";
RL   Cell 62:379-390(1990).
RN   [2]
RP   SEQUENCE REVISION.
RA   Meurs E.;
RL   Submitted (AUG-1990) to the EMBL/GenBank/DDBJ databases.
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RX   MEDLINE=92230231; PubMed=1373553; DOI=10.1016/0042-6822(92)90732-5;
RA   Thomis D.C., Doohan J.P., Samuel C.E.;
RT   "Mechanism of interferon action: cDNA structure, expression, and
RT   regulation of the interferon-induced, RNA-dependent P1/eIF-2 alpha
RT   protein kinase from human cells.";
RL   Virology 188:33-46(1992).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA / MRNA].
RX   MEDLINE=97080568; PubMed=8921913; DOI=10.1016/0378-1119(96)00314-9;
RA   Kuhen K.L., Shen X., Samuel C.E.;
RT   "Mechanism of interferon action sequence of the human interferon-
RT   inducible RNA-dependent protein kinase (PKR) deduced from genomic
RT   clones.";
RL   Gene 178:191-193(1996).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RC   TISSUE=Placenta;
RX   MEDLINE=96411668; PubMed=8812437; DOI=10.1006/geno.1996.0446;
RA   Kuhen K.L., Shen X., Carlisle E.R., Richardson A.L., Weier H.-U.G.,
RA   Tanaka H., Samuel C.E.;
RT   "Structural organization of the human gene (PKR) encoding an
RT   interferon-inducible RNA-dependent protein kinase (PKR) and
RT   differences from its mouse homolog.";
RL   Genomics 36:197-201(1996).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   MEDLINE=98393043; PubMed=9726442; DOI=10.1089/jir.1998.18.609;
RA   Xu Z., Williams B.R.;
RT   "Genomic features of human PKR: alternative splicing and a polymorphic
RT   CGG repeat in the 5'-untranslated region.";
RL   J. Interferon Cytokine Res. 18:609-616(1998).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Brain, and Embryo;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RG   NIEHS SNPs program;
RL   Submitted (JAN-2003) to the EMBL/GenBank/DDBJ databases.
RN   [9]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15815621; DOI=10.1038/nature03466;
RA   Hillier L.W., Graves T.A., Fulton R.S., Fulton L.A., Pepin K.H.,
RA   Minx P., Wagner-McPherson C., Layman D., Wylie K., Sekhon M.,
RA   Becker M.C., Fewell G.A., Delehaunty K.D., Miner T.L., Nash W.E.,
RA   Kremitzki C., Oddy L., Du H., Sun H., Bradshaw-Cordum H., Ali J.,
RA   Carter J., Cordes M., Harris A., Isak A., van Brunt A., Nguyen C.,
RA   Du F., Courtney L., Kalicki J., Ozersky P., Abbott S., Armstrong J.,
RA   Belter E.A., Caruso L., Cedroni M., Cotton M., Davidson T., Desai A.,
RA   Elliott G., Erb T., Fronick C., Gaige T., Haakenson W., Haglund K.,
RA   Holmes A., Harkins R., Kim K., Kruchowski S.S., Strong C.M.,
RA   Grewal N., Goyea E., Hou S., Levy A., Martinka S., Mead K.,
RA   McLellan M.D., Meyer R., Randall-Maher J., Tomlinson C.,
RA   Dauphin-Kohlberg S., Kozlowicz-Reilly A., Shah N.,
RA   Swearengen-Shahid S., Snider J., Strong J.T., Thompson J., Yoakum M.,
RA   Leonard S., Pearman C., Trani L., Radionenko M., Waligorski J.E.,
RA   Wang C., Rock S.M., Tin-Wollam A.-M., Maupin R., Latreille P.,
RA   Wendl M.C., Yang S.-P., Pohl C., Wallis J.W., Spieth J., Bieri T.A.,
RA   Berkowicz N., Nelson J.O., Osborne J., Ding L., Meyer R., Sabo A.,
RA   Shotland Y., Sinha P., Wohldmann P.E., Cook L.L., Hickenbotham M.T.,
RA   Eldred J., Williams D., Jones T.A., She X., Ciccarelli F.D.,
RA   Izaurralde E., Taylor J., Schmutz J., Myers R.M., Cox D.R., Huang X.,
RA   McPherson J.D., Mardis E.R., Clifton S.W., Warren W.C.,
RA   Chinwalla A.T., Eddy S.R., Marra M.A., Ovcharenko I., Furey T.S.,
RA   Miller W., Eichler E.E., Bork P., Suyama M., Torrents D.,
RA   Waterston R.H., Wilson R.K.;
RT   "Generation and annotation of the DNA sequences of human chromosomes 2
RT   and 4.";
RL   Nature 434:724-731(2005).
RN   [10]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Brain;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [11]
RP   PROTEIN SEQUENCE OF 2-18; 27-40; 70-77; 414-426 AND 430-440, CLEAVAGE
RP   OF INITIATOR METHIONINE, ACETYLATION AT ALA-2, AND MASS SPECTROMETRY.
RC   TISSUE=Prostatic carcinoma;
RA   Bienvenut W.V., Gao M., Leug H.;
RL   Submitted (JUN-2009) to UniProtKB.
RN   [12]
RP   INTERACTION WITH DNAJC3.
RX   MEDLINE=96139509; PubMed=8576172; DOI=10.1074/jbc.271.3.1702;
RA   Polyak S.J., Tang N., Wambach M., Barber G.N., Katze M.G.;
RT   "The P58 cellular inhibitor complexes with the interferon-induced,
RT   double-stranded RNA-dependent protein kinase, PKR, to regulate its
RT   autophosphorylation and activity.";
RL   J. Biol. Chem. 271:1702-1707(1996).
RN   [13]
RP   INTERACTION WITH HIV-1 TAT.
RX   PubMed=9079663; DOI=10.1074/jbc.272.13.8388;
RA   Brand S.R., Kobayashi R., Mathews M.B.;
RT   "The Tat protein of human immunodeficiency virus type 1 is a substrate
RT   and inhibitor of the interferon-induced, virally activated protein
RT   kinase, PKR.";
RL   J. Biol. Chem. 272:8388-8395(1997).
RN   [14]
RP   INTERACTION WITH HCV NS5A.
RX   MEDLINE=97288299; PubMed=9143277; DOI=10.1006/viro.1997.8493;
RA   Gale M.J. Jr., Korth M.J., Tang N.M., Tan S.-L., Hopkins D.A.,
RA   Dever T.E., Polyak S.J., Gretch D.R., Katze M.G.;
RT   "Evidence that hepatitis C virus resistance to interferon is mediated
RT   through repression of the PKR protein kinase by the nonstructural 5A
RT   protein.";
RL   Virology 230:217-227(1997).
RN   [15]
RP   INTERACTION WITH INFLUENZA A NS1 PROTEIN.
RX   PubMed=9781815; DOI=10.1089/jir.1998.18.757;
RA   Tan S.L., Katze M.G.;
RT   "Biochemical and genetic evidence for complex formation between the
RT   influenza A virus NS1 protein and the interferon-induced PKR protein
RT   kinase.";
RL   J. Interferon Cytokine Res. 18:757-766(1998).
RN   [16]
RP   INTERACTION WITH HCV E2 ENVELOPE PROTEIN.
RX   MEDLINE=99322192; PubMed=10390359; DOI=10.1126/science.285.5424.107;
RA   Taylor D.R., Shi S.T., Romano P.R., Barber G.N., Lai M.M.C.;
RT   "Inhibition of the interferon-inducible protein kinase PKR by HCV E2
RT   protein.";
RL   Science 285:107-110(1999).
RN   [17]
RP   PHOSPHORYLATION AT SER-83; THR-88; THR-89; THR-90; SER-242; THR-255
RP   AND THR-258, MUTAGENESIS OF SER-83; THR-88; THR-89; THR-90; SER-242;
RP   THR-255; THR-258 AND LYS-296, AND INHIBITION BY HCV E2 ENVELOPE
RP   PROTEIN.
RX   MEDLINE=20583813; PubMed=11152499;
RX   DOI=10.1128/JVI.75.3.1265-1273.2001;
RA   Taylor D.R., Tian B., Romano P.R., Hinnebusch A.G., Lai M.M.C.,
RA   Mathews M.B.;
RT   "Hepatitis C virus envelope protein E2 does not inhibit PKR by simple
RT   competition with autophosphorylation sites in the RNA-binding
RT   domain.";
RL   J. Virol. 75:1265-1273(2001).
RN   [18]
RP   MUTAGENESIS, AND PHOSPHORYLATION AT THR-446 AND THR-451.
RX   MEDLINE=21326157; PubMed=11337501; DOI=10.1074/jbc.M102108200;
RA   Zhang F., Romano P.R., Nagamura-Inoue T., Tian B., Dever T.E.,
RA   Mathews M.B., Ozato K., Hinnebusch A.G.;
RT   "Binding of double-stranded RNA to protein kinase PKR is required for
RT   dimerization and promotes critical autophosphorylation events in the
RT   activation loop.";
RL   J. Biol. Chem. 276:24946-24958(2001).
RN   [19]
RP   INHIBITION BY VACCINIA VIRUS PROTEIN E3.
RX   PubMed=15207627; DOI=10.1016/j.virol.2004.03.012;
RA   Langland J.O., Jacobs B.L.;
RT   "Inhibition of PKR by vaccinia virus: role of the N- and C-terminal
RT   domains of E3L.";
RL   Virology 324:419-429(2004).
RN   [20]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-83 AND SER-456, AND MASS
RP   SPECTROMETRY.
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [21]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RA   Colinge J., Superti-Furga G., Bennett K.L.;
RL   Submitted (OCT-2008) to UniProtKB.
RN   [22]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-83, AND MASS
RP   SPECTROMETRY.
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [23]
RP   STRUCTURE BY NMR OF 1-175.
RX   MEDLINE=98409549; PubMed=9736623; DOI=10.1093/emboj/17.18.5458;
RA   Nanduri S., Carpick B.W., Yang Y., Williams B.R.G., Qin J.;
RT   "Structure of the double-stranded RNA-binding domain of the protein
RT   kinase PKR reveals the molecular basis of its dsRNA-mediated
RT   activation.";
RL   EMBO J. 17:5458-5465(1998).
RN   [24]
RP   X-RAY CRYSTALLOGRAPHY (2.5 ANGSTROMS) OF 258-550 IN COMPLEX WITH
RP   EIF2ALPHA, AND PHOSPHORYLATION AT THR-446.
RX   PubMed=16179258; DOI=10.1016/j.cell.2005.06.044;
RA   Dar A.C., Dever T.E., Sicheri F.;
RT   "Higher-order substrate recognition of eIF2alpha by the RNA-dependent
RT   protein kinase PKR.";
RL   Cell 122:887-900(2005).
RN   [25]
RP   VARIANTS [LARGE SCALE ANALYSIS] GLU-428; VAL-439 AND VAL-506.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C.,
RA   Bignell G., Davies H., Teague J., Butler A., Stevens C., Edkins S.,
RA   O'Meara S., Vastrik I., Schmidt E.E., Avis T., Barthorpe S.,
RA   Bhamra G., Buck G., Choudhury B., Clements J., Cole J., Dicks E.,
RA   Forbes S., Gray K., Halliday K., Harrison R., Hills K., Hinton J.,
RA   Jenkinson A., Jones D., Menzies A., Mironenko T., Perry J., Raine K.,
RA   Richardson D., Shepherd R., Small A., Tofts C., Varian J., Webb T.,
RA   West S., Widaa S., Yates A., Cahill D.P., Louis D.N., Goldstraw P.,
RA   Nicholson A.G., Brasseur F., Looijenga L., Weber B.L., Chiew Y.-E.,
RA   DeFazio A., Greaves M.F., Green A.R., Campbell P., Birney E.,
RA   Easton D.F., Chenevix-Trench G., Tan M.-H., Khoo S.K., Teh B.T.,
RA   Yuen S.T., Leung S.Y., Wooster R., Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
CC   -!- FUNCTION: Following activation by double-stranded RNA in the
CC       presence of ATP, the kinase becomes autophosphorylated and can
CC       catalyze the phosphorylation of the translation initiation factor
CC       EIF2S1, which leads to an inhibition of the initiation of protein
CC       synthesis. Double-stranded RNA is generated during the course of a
CC       viral infection.
CC   -!- CATALYTIC ACTIVITY: ATP + a protein = ADP + a phosphoprotein.
CC   -!- ENZYME REGULATION: Activity is markedly stimulated by manganese
CC       ions. Besides dsRNA, heparin is a potent activator of the kinase.
CC       Binding to dsRNA is required for dimerization leading to
CC       autophosphorylation in the activation loop and stimulation of
CC       function. Inhibited by vaccinia virus protein E3, probably via
CC       dsRNA sequestering.
CC   -!- SUBUNIT: Homodimer. Interacts with STRBP (By similarity).
CC       Interacts with DNAJC3. Inhibited by direct interaction with viral
CC       proteins such as HCV E2, HCV NS5A and influenza A NS1. Activated
CC       by the interaction with HIV-1 Tat.
CC   -!- INTERACTION:
CC       Q9UJU6:DBNL; NbExp=1; IntAct=EBI-640775, EBI-751783;
CC       Q27968:DNAJC3 (xeno); NbExp=3; IntAct=EBI-640775, EBI-640793;
CC       P05198:EIF2S1; NbExp=1; IntAct=EBI-640775, EBI-1056162;
CC       P35570:Irs1 (xeno); NbExp=1; IntAct=EBI-640775, EBI-520230;
CC   -!- INDUCTION: By interferons alpha.
CC   -!- PTM: Autophosphorylated on several Ser and Thr residues.
CC       Autophosphorylation of Thr-451 is dependent on Thr-446 and is
CC       stimulated by dsRNA binding and dimerization. Autophosphorylation
CC       apparently leads to the activation of the kinase.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. Ser/Thr
CC       protein kinase family. GCN2 subfamily.
CC   -!- SIMILARITY: Contains 2 DRBM (double-stranded RNA-binding) domains.
CC   -!- SIMILARITY: Contains 1 protein kinase domain.
CC   -!- WEB RESOURCE: Name=NIEHS-SNPs;
CC       URL="http://egp.gs.washington.edu/data/prkr/";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; M35663; AAA36409.1; -; mRNA.
DR   EMBL; M85294; AAA18253.1; -; mRNA.
DR   EMBL; U50648; AAC50768.1; -; Genomic_DNA.
DR   EMBL; U50634; AAC50768.1; JOINED; Genomic_DNA.
DR   EMBL; U50635; AAC50768.1; JOINED; Genomic_DNA.
DR   EMBL; U50636; AAC50768.1; JOINED; Genomic_DNA.
DR   EMBL; U50637; AAC50768.1; JOINED; Genomic_DNA.
DR   EMBL; U50638; AAC50768.1; JOINED; Genomic_DNA.
DR   EMBL; U50639; AAC50768.1; JOINED; Genomic_DNA.
DR   EMBL; U50640; AAC50768.1; JOINED; Genomic_DNA.
DR   EMBL; U50641; AAC50768.1; JOINED; Genomic_DNA.
DR   EMBL; U50642; AAC50768.1; JOINED; Genomic_DNA.
DR   EMBL; U50643; AAC50768.1; JOINED; Genomic_DNA.
DR   EMBL; U50644; AAC50768.1; JOINED; Genomic_DNA.
DR   EMBL; U50645; AAC50768.1; JOINED; Genomic_DNA.
DR   EMBL; U50646; AAC50768.1; JOINED; Genomic_DNA.
DR   EMBL; U50647; AAC50768.1; JOINED; Genomic_DNA.
DR   EMBL; AF167472; AAF13156.1; -; Genomic_DNA.
DR   EMBL; AF167460; AAF13156.1; JOINED; Genomic_DNA.
DR   EMBL; AF167462; AAF13156.1; JOINED; Genomic_DNA.
DR   EMBL; AF167463; AAF13156.1; JOINED; Genomic_DNA.
DR   EMBL; AF167464; AAF13156.1; JOINED; Genomic_DNA.
DR   EMBL; AF167465; AAF13156.1; JOINED; Genomic_DNA.
DR   EMBL; AF167466; AAF13156.1; JOINED; Genomic_DNA.
DR   EMBL; AF167468; AAF13156.1; JOINED; Genomic_DNA.
DR   EMBL; AF167470; AAF13156.1; JOINED; Genomic_DNA.
DR   EMBL; AK290655; BAF83344.1; -; mRNA.
DR   EMBL; AK313818; BAG36554.1; -; mRNA.
DR   EMBL; AY228338; AAO38055.1; -; Genomic_DNA.
DR   EMBL; AC007899; AAY24317.1; -; Genomic_DNA.
DR   EMBL; BC093676; AAH93676.1; -; mRNA.
DR   EMBL; BC101475; AAI01476.1; -; mRNA.
DR   IPI; IPI00019463; -.
DR   PIR; JC5225; JC5225.
DR   RefSeq; NP_001129123.1; -.
DR   RefSeq; NP_001129124.1; -.
DR   RefSeq; NP_002750.1; -.
DR   UniGene; Hs.131431; -.
DR   PDB; 1QU6; NMR; -; A=1-170.
DR   PDB; 2A19; X-ray; 2.50 A; B/C=258-550.
DR   PDB; 2A1A; X-ray; 2.80 A; B=258-550.
DR   PDBsum; 1QU6; -.
DR   PDBsum; 2A19; -.
DR   PDBsum; 2A1A; -.
DR   ProteinModelPortal; P19525; -.
DR   SMR; P19525; 257-541.
DR   DIP; DIP-2657N; -.
DR   IntAct; P19525; 8.
DR   MINT; MINT-92415; -.
DR   STRING; P19525; -.
DR   PhosphoSite; P19525; -.
DR   PRIDE; P19525; -.
DR   Ensembl; ENST00000233057; ENSP00000233057; ENSG00000055332.
DR   Ensembl; ENST00000395127; ENSP00000378559; ENSG00000055332.
DR   GeneID; 5610; -.
DR   KEGG; hsa:5610; -.
DR   NMPDR; fig|9606.3.peg.17745; -.
DR   UCSC; uc002rps.1; human.
DR   CTD; 5610; -.
DR   GeneCards; GC02M037246; -.
DR   H-InvDB; HIX0029806; -.
DR   HGNC; HGNC:9437; EIF2AK2.
DR   HPA; CAB003845; -.
DR   HPA; HPA019795; -.
DR   MIM; 176871; gene.
DR   PharmGKB; PA33779; -.
DR   eggNOG; prNOG05060; -.
DR   HOGENOM; HBG755398; -.
DR   HOVERGEN; HBG051430; -.
DR   InParanoid; P19525; -.
DR   OMA; KHRIDGK; -.
DR   OrthoDB; EOG91K1XP; -.
DR   PhylomeDB; P19525; -.
DR   BRENDA; 2.7.11.1; 247.
DR   Reactome; REACT_6167; Influenza Infection.
DR   NextBio; 21806; -.
DR   PMAP-CutDB; P19525; -.
DR   ArrayExpress; P19525; -.
DR   Bgee; P19525; -.
DR   CleanEx; HS_EIF2AK2; -.
DR   Genevestigator; P19525; -.
DR   GermOnline; ENSG00000055332; Homo sapiens.
DR   GO; GO:0005622; C:intracellular; IEA:InterPro.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0003725; F:double-stranded RNA binding; TAS:ProtInc.
DR   GO; GO:0004694; F:eukaryotic translation initiation factor 2a...; TAS:ProtInc.
DR   GO; GO:0005515; F:protein binding; IPI:IntAct.
DR   GO; GO:0008601; F:protein phosphatase type 2A regulator activity; TAS:ProtInc.
DR   GO; GO:0044419; P:interspecies interaction between organisms; IEA:UniProtKB-KW.
DR   GO; GO:0033689; P:negative regulation of osteoblast prolifera...; IMP:UniProtKB.
DR   GO; GO:0046777; P:protein amino acid autophosphorylation; IMP:UniProtKB.
DR   GO; GO:0009615; P:response to virus; IEA:UniProtKB-KW.
DR   InterPro; IPR001159; Ds-RNA-bd.
DR   InterPro; IPR014720; dsRNA-bd-like.
DR   InterPro; IPR011009; Kinase-like_dom.
DR   InterPro; IPR000719; Prot_kinase_cat_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR017442; Se/Thr_prot_kinase-like_dom.
DR   InterPro; IPR008271; Ser/Thr_prot_kinase_AS.
DR   Gene3D; G3DSA:3.30.160.20; dsRNA-bd-like; 2.
DR   Pfam; PF00035; dsrm; 2.
DR   Pfam; PF00069; Pkinase; 1.
DR   SMART; SM00358; DSRM; 2.
DR   SUPFAM; SSF56112; Kinase_like; 1.
DR   PROSITE; PS50137; DS_RBD; 2.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00108; PROTEIN_KINASE_ST; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Antiviral defense; ATP-binding;
KW   Complete proteome; Direct protein sequencing; Host-virus interaction;
KW   Kinase; Nucleotide-binding; Phosphoprotein; Polymorphism; Repeat;
KW   RNA-binding; Serine/threonine-protein kinase; Transferase.
FT   INIT_MET      1      1       Removed.
FT   CHAIN         2    551       Interferon-induced, double-stranded RNA-
FT                                activated protein kinase.
FT                                /FTId=PRO_0000085945.
FT   DOMAIN        9     77       DRBM 1.
FT   DOMAIN      100    167       DRBM 2.
FT   DOMAIN      267    538       Protein kinase.
FT   REPEAT      331    343       1.
FT   REPEAT      345    357       2.
FT   NP_BIND     273    281       ATP (By similarity).
FT   REGION      331    357       2 X 13 AA approximate repeats.
FT   ACT_SITE    414    414       Proton acceptor (By similarity).
FT   BINDING     296    296       ATP.
FT   MOD_RES       2      2       N-acetylalanine.
FT   MOD_RES      83     83       Phosphoserine; by autocatalysis
FT                                (Probable).
FT   MOD_RES      88     88       Phosphothreonine; by autocatalysis
FT                                (Probable).
FT   MOD_RES      89     89       Phosphothreonine; by autocatalysis
FT                                (Probable).
FT   MOD_RES      90     90       Phosphothreonine; by autocatalysis
FT                                (Probable).
FT   MOD_RES     242    242       Phosphoserine; by autocatalysis
FT                                (Probable).
FT   MOD_RES     255    255       Phosphothreonine; by autocatalysis
FT                                (Probable).
FT   MOD_RES     258    258       Phosphothreonine; by autocatalysis
FT                                (Probable).
FT   MOD_RES     446    446       Phosphothreonine; by autocatalysis.
FT   MOD_RES     451    451       Phosphothreonine; by autocatalysis.
FT   MOD_RES     456    456       Phosphoserine.
FT   VARIANT     428    428       V -> E (in dbSNP:rs56219559).
FT                                /FTId=VAR_040474.
FT   VARIANT     439    439       L -> V (in a lung adenocarcinoma sample;
FT                                somatic mutation).
FT                                /FTId=VAR_040475.
FT   VARIANT     506    506       I -> V (in dbSNP:rs34821155).
FT                                /FTId=VAR_040476.
FT   MUTAGEN      59     60       SK->AA: In FL-PKR-2AI; moderate loss of
FT                                activity but no effect on dsRNA binding.
FT   MUTAGEN      60     60       K->A: Impairs dsRNA binding but not
FT                                dimerization or activity.
FT   MUTAGEN      67     67       A->E: Significant loss of activity; loss
FT                                of dsRNA binding and dimerization.
FT   MUTAGEN      83     83       S->A: No effect on enzymatic activity;
FT                                when associated with A-88; A-89 and A-90.
FT   MUTAGEN      88     88       T->A: No effect on enzymatic activity;
FT                                when associated with A-83; A-89 and A-90.
FT   MUTAGEN      89     89       T->A: No effect on enzymatic activity;
FT                                when associated with A-83; A-88 and A-90.
FT   MUTAGEN      90     90       T->A: No effect on enzymatic activity;
FT                                when associated with A-83; A-88 and A-89.
FT   MUTAGEN     149    150       TK->AA: In FL-PKR-2AII; no effect on
FT                                activity.
FT   MUTAGEN     242    242       S->A: Moderate loss of activity; when
FT                                associated with A-255 and A-258.
FT   MUTAGEN     244    296       Missing: Loss of activity.
FT   MUTAGEN     255    255       T->A: Moderate loss of activity; when
FT                                associated with A-242 and A-255.
FT   MUTAGEN     258    258       T->A: Moderate loss of activity.
FT   MUTAGEN     296    296       K->R: Loss of activity.
FT   MUTAGEN     446    446       T->A: Significant loss of activity and
FT                                impairs autophosphorylation of T-451.
FT   MUTAGEN     451    451       T->A: Loss of activity.
FT   CONFLICT    512    512       K -> E (in Ref. 6; AAF13156).
FT   STRAND        5      7
FT   HELIX        10     21
FT   STRAND       26     32
FT   TURN         35     37
FT   STRAND       41     50
FT   STRAND       54     56
FT   HELIX        61     76
FT   HELIX       102    111
FT   STRAND      115    123
FT   STRAND      125    138
FT   STRAND      144    149
FT   HELIX       150    167
FT   HELIX       261    266
FT   STRAND      267    274
FT   STRAND      276    278
FT   STRAND      281    286
FT   TURN        287    289
FT   STRAND      292    299
FT   HELIX       303    305
FT   HELIX       306    314
FT   STRAND      323    332
FT   STRAND      358    366
FT   HELIX       374    380
FT   HELIX       381    383
FT   HELIX       388    407
FT   HELIX       417    419
FT   STRAND      420    424
FT   STRAND      427    430
FT   STRAND      437    440
FT   HELIX       457    461
FT   HELIX       468    482
FT   HELIX       488    499
FT   HELIX       509    518
FT   HELIX       523    525
FT   HELIX       529    539
SQ   SEQUENCE   551 AA;  62094 MW;  815AD83ACAB45DA3 CRC64;
     MAGDLSAGFF MEELNTYRQK QGVVLKYQEL PNSGPPHDRR FTFQVIIDGR EFPEGEGRSK
     KEAKNAAAKL AVEILNKEKK AVSPLLLTTT NSSEGLSMGN YIGLINRIAQ KKRLTVNYEQ
     CASGVHGPEG FHYKCKMGQK EYSIGTGSTK QEAKQLAAKL AYLQILSEET SVKSDYLSSG
     SFATTCESQS NSLVTSTLAS ESSSEGDFSA DTSEINSNSD SLNSSSLLMN GLRNNQRKAK
     RSLAPRFDLP DMKETKYTVD KRFGMDFKEI ELIGSGGFGQ VFKAKHRIDG KTYVIKRVKY
     NNEKAEREVK ALAKLDHVNI VHYNGCWDGF DYDPETSDDS LESSDYDPEN SKNSSRSKTK
     CLFIQMEFCD KGTLEQWIEK RRGEKLDKVL ALELFEQITK GVDYIHSKKL IHRDLKPSNI
     FLVDTKQVKI GDFGLVTSLK NDGKRTRSKG TLRYMSPEQI SSQDYGKEVD LYALGLILAE
     LLHVCDTAFE TSKFFTDLRD GIISDIFDKK EKTLLQKLLS KKPEDRPNTS EILRTLTVWK
     KSPEKNERHT C
//
